A limited-size clinical trial in Johannesburg suggests that the Oxford–AstraZeneca COVID-19 vaccine is weak against the 501.V2 variant of SARS-CoV-2. (The Wall Street Journal) Oxford–AstraZeneca COVID-19 vaccineCOVID-19 vaccineCOVID-19 pandemic link embed save